Shares of psychedelic-related biotech companies are trading higher amid sympathy with AtaiBeckley after the company announced it will be acquired by Lilly in a deal worth up to $3.8 billion.

Benzinga Newsdesk www.benzinga.com Positive 94.3%

Neg 0% Neu 0% Pos 94.3%

Comments

No comments yet. Be the first!